Literature DB >> 25701727

Redox-responsive mesoporous silica as carriers for controlled drug delivery: a comparative study based on silica and PEG gatekeepers.

Ying Wang1, Ning Han1, Qinfu Zhao1, Ling Bai1, Jia Li1, Tongying Jiang1, Siling Wang2.   

Abstract

Hybrid mesoporous silica nanoparticles (MSNs) modified with polymer polyethylene glycol (PEG) through the biodegradable disulfide bonds were prepared to achieve 'on demand' drug release. In this system, PEG chains were chosen as the representative gatekeepers that can block drugs within the mesopores of MSNs. After the addition of glutathione (GSH), the gatekeepers were removed from the pore outlets of MSNs, followed by the release of encapsulated drugs. In this research, the effects of grafting density of gatekeepers on the drug release and biocompatibility of silica carriers were also investigated. First, PEG modified MSNs were prepared by the condensation reaction between the carboxyl groups of MSN and the hydroxyl of PEG. The structure of the resultant MSN-SS-PEG was characterized by transmission electron microscopy (TEM), nitrogen adsorption/desorption isotherms analysis and Fourier transform infrared spectroscopy (FTIR). Rhodamine B (RhB) as the model drug was loaded into MSNs. The in vitro assay results indicated that RhB was released rapidly after the addition of 10 mM GSH; M1-SS-PEG had the best capping efficiency compared with M0.5 and M1.5 groups. Moreover, hemolysis assay, serum protein adsorption and cell viability test indicated that with the increase of PEG grafting density, the biocompatibility of silica carriers increased.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biocompatibility; Controlled drug delivery; Gatekeepers; Mesoporous silica nanoparticles; Redox-responsive

Mesh:

Substances:

Year:  2015        PMID: 25701727     DOI: 10.1016/j.ejps.2015.02.008

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

Review 1.  How Advancing are Mesoporous Silica Nanoparticles? A Comprehensive Review of the Literature.

Authors:  Sahar Porrang; Soodabeh Davaran; Nader Rahemi; Somaiyeh Allahyari; Ebrahim Mostafavi
Journal:  Int J Nanomedicine       Date:  2022-04-22

2.  Study on the formation and properties of red blood cell-like Fe3O4/TbLa3(Bim)12/PLGA composite particles.

Authors:  Ping Li; Bing Qi; Kun Li; Junwei Xu; Meili Liu; Xuenan Gu; Xufeng Niu; Yubo Fan
Journal:  RSC Adv       Date:  2018-04-03       Impact factor: 4.036

Review 3.  Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances.

Authors:  Reema Narayan; Usha Y Nayak; Ashok M Raichur; Sanjay Garg
Journal:  Pharmaceutics       Date:  2018-08-06       Impact factor: 6.321

4.  Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance.

Authors:  Yuetong Wang; Hsin-Yi Huang; Liu Yang; Zhanxia Zhang; Hongbin Ji
Journal:  Sci Rep       Date:  2016-05-06       Impact factor: 4.379

5.  Efficient Self-Assembly of mPEG End-Capped Porous Silica as a Redox-Sensitive Nanocarrier for Controlled Doxorubicin Delivery.

Authors:  Anh Khoa Nguyen; Thi Hiep Nguyen; Bui Quoc Bao; Long Giang Bach; Dai Hai Nguyen
Journal:  Int J Biomater       Date:  2018-03-01

Review 6.  Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy.

Authors:  Xiufeng Cong; Jun Chen; Ran Xu
Journal:  Front Bioeng Biotechnol       Date:  2022-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.